Evora Biosciences

Evora Biosciences develops first-in-class anti-inflammatory peptides, with a focus on so-called "un-druggable targets" in multi-billion therapeutic areas.

Its lead API, EVO-003, is the world's first universal TLR-4 inhibitor. A true pipeline-in-a-product asset, EVO-003 has the potential to adress a large array of indications, and already exhibits exciting preclinical data in vitro and in vivo in various models (ARDS, sepsis, chemotherapy-induced ototoxicity, skin inflammation, eye inflammation e.g).

Evora Biosciences aims to start clinical trials in 2026.